Drug intelligence / Profile preview

Caffeinated coffee

Development stage: Phase 2
Lead developer: Aspire Biopharma
Administration: Oral

Overview

Caffeinated coffee is a widely consumed beverage hypothesized to increase energy expenditure and lead to positive metabolic effects. It contains caffeine, a stimulant, and other bioactive compounds. Research has explored its potential role in modulating irisin levels, a hormone involved in energy metabolism, and its association with metabolic profiles in humans. A randomized trial (NCT00305097) investigated the effects of consuming 5 cups per day of instant caffeinated coffee on irisin levels and metabolic profiles in healthy, overweight coffee drinkers.

Brand names: Coffea Tosta
Other names: coffeacoffea arabicacoffea canephorajavabrewcup of joe

Targets

PDE (Phosphodiesterase family)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Caffeinated coffee.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caffeinated coffee.

Explore the full profile